Condition
Refractory Metastatic Digestive System Carcinoma
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Surufatinibtoripalimab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Unknown1
Clinical Trials (1)
Research Network
Common Treatments
- Surufatinibtoripalimab1
Active Sponsors
- Peking University1
Top Investigators
Peking University Cancer Hospital & Institute
Related Conditions
- Primary Peritoneal Cancer1